Physicians' Academy for Cardiovascular Education

LDL-c: new insights into its role as causal risk factor and target for therapy

10' education - Nov. 11, 2022 - Prof. Brian Ference, MD - Cambridge, UK

Video navigation menu

  • Cumulative exposure hypothesis of ASCVD 0:59
  • Lifetime risk 3:01
  • Therapies to reduce ASCVD risk with early sustained LDL lowering 4:48
  • Who should be targeted? 5:29


Show transcript

Educational information

This lecture by Brian Ference was part of the EBAC-accredited symposium "A decade of innovation, guidelines and paradigm shifts in LDL-c management" held during the ESC congress 2022.


Prof. Brian A. Ference, M.D, Professor and Director of Research in Translational Therapeutics, Executive Director, Centre for Naturally Randomized Trials, University of Cambridge, United Kingdom


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.


Funding for this educational program was provided by unrestricted educational grants from Daiichi-Sankyo, New Amsterdam Pharma, Novartis, Sanofi & Ultragenyx.

View slides of this presentation

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: